转自：北京日报客户端 对于新增的114种药品，陈昊强调，对患者而言，医保目录动态调整且总体呈增多趋势，临床医生和患 者的用药选择性都得到增强，能更好满足患者需求，尤其是创新药纳入速度和数量增加，这是非常积极 的现象。虽然创新药纳入会给医保基金带来一定支付压力，但医保部门有总额预算控制、DRG/DIP单病 种付费打包机制以及合理用药管理等多种管理工具，只要临床坚持合理用药，短时内不会对医保基金造 成太大压力，医保基金承受是没有太大问题的。 "未来，患者需要听从医务人员等专业人员的指导，由临床专业人士判断原有用药是否需要延续，并制 定和调整用药方案，切勿自行用药。医保目录内药品均为处方药，具体用药种类和方式需由医务人员决 定，患者应信任医务人员和医学技术，无需过度担忧。"陈昊说。 来源：人民日报健康客户端 作者: 高瑞瑞 一位居民 正在当地医院窗口处取药。高瑞瑞摄 记者了解到，被调出的29种药中，有21种西药和8种中成药，多款药品都在医保目录中有替代选项。华 中科技大学同济医学院药品政策与管理研究中心主任、高级经济师陈昊告诉人民日报健康客户端记 者，"医保目录实行动态调整，这是正常现象。"华中科技大学同济医学院药 ...

据央视 企业研发投入有了稳定的回报预期,将激励更多药企加大创新研发力度,尤其是针对肿瘤、罕见病等未被 满足的临床需求领域。我国一家制药企业今年有7款创新药进入国家基本医保目录。 国家医保局统计,新药从获批上市到纳入医保目录,获得报销的时间已经从原来的5年左右缩短到一年左 右,大约80%的创新药能够在上市之后的两年内纳入到医保药品目录。医保准入成为药企市场拓展的关 键,一方面创新药通过纳入医保快速放量,而另一方面临床价值不高、有替代药的药品被调出目录,通 过"腾笼换鸟"实现资源优化配置,推动医药行业向高质量、创新型方向转型。 目前,2025年国家医保药品目录内药品总数已达3253种,其中1类创新药数量增至50种。 目前,我国已建立每年一调的医保目录动态调整机制,申报范围主要聚焦5年内新上市的药品。2025年新纳 入医保目录的114种药品中,多个实现了当年获批上市,当年进入医保目录。 2018年以来,我国1类创新药获批数量呈明显的上升趋势,2024年达到48种,是2018年的5倍以上,医保目录已 成为创新药快速落地的"加速器",推动我国创新药市场持续扩容。 ...

国家医保局统计，新药从获批上市到纳入医保目录，获得报销的时间已经从原来的5年左右缩短到一年左右，大约80%的创新药 能够在上市之后的两年内纳入到医保药品目录。医保准入成为药企市场拓展的关键，一方面创新药通过纳入医保快速放量，而另一方 面临床价值不高、有替代药的药品被调出目录，通过"腾笼换鸟"实现资源优化配置，推动医药行业向高质量、创新型方向转型。 目前，2025年国家医保药品目录内药品总数已达3253种，其中1类创新药数量增至50种。 企业研发投入有了稳定的回报预期，将激励更多药企加大创新研发力度，尤其是针对肿瘤、罕见病等未被满足的临床需求领域。 这家制药企业今年有7款创新药进入国家基本医保目录。 2018以来，我国1类创新药获批数量呈明显的上升趋势，2024年达到48种，是2018年的5倍以上，医保目录已成为创新药快速落地 的"加速器"，推动我国创新药市场持续扩容。这家制药企业自主研发的一款填补国内临床空白的国家1类新药，这次通过医保谈判进 入国家基本医保目录。 央视网消息：目前，我国已建立每年一调的医保目录动态调整机制，申报范围主要聚焦5年内新上市的药品。2025年新纳入医保 目录的114种药品中，多个实 ...

Core Viewpoint - During the "14th Five-Year Plan" period, China's medical insurance system has made significant progress in addressing urgent issues faced by the public, enhancing accessibility and affordability of medical services and medications [1][17]. Group 1: Medical Insurance Achievements - The implementation of centralized bulk purchasing and dynamic adjustments to the medical insurance drug list has enabled patients to access affordable medications and new treatments [1][5]. - The number of people benefiting from cross-provincial direct settlement of medical expenses has surged from 5.37 million in 2020 to 238 million in 2024, marking a 44-fold increase [13]. - The total expenditure of the medical insurance fund reached 12.13 trillion yuan during the "14th Five-Year Plan," with an average annual growth rate of 9.1% [15]. Group 2: Impact on Patients - The introduction of centralized procurement for high-value medical consumables, such as cochlear implants, has significantly reduced costs, with prices dropping from over 200,000 yuan to around 50,000 yuan [3][5]. - Innovative drugs, such as the newly approved treatment for rare lung cancer, have been included in the medical insurance directory, reducing patient costs from full out-of-pocket expenses to minimal payments after insurance coverage [9][11]. - The medical insurance coverage has expanded to include outpatient treatments for chronic diseases, providing greater financial relief for patients [11][13]. Group 3: Future Directions - The 11th batch of centralized procurement is underway, focusing on optimizing measures to ensure quality and affordability while promoting fair competition among pharmaceutical companies [7][9]. - The continuous improvement of the medical insurance system aims to enhance the accessibility and quality of healthcare services, ultimately contributing to the development of a healthier society [17].

Core Viewpoint - The National Healthcare Security Administration (NHSA) has introduced measures to support the high-quality development of innovative drugs, focusing on enhancing research support, facilitating access to insurance, and encouraging clinical application [1][2]. Summary by Relevant Sections Support for Innovative Drug Development - The NHSA has outlined 16 measures across five key areas to bolster innovative drug development, including support for research, inclusion in insurance directories, and enhancing payment capabilities [1][2]. - Approximately 80% of innovative drugs can be included in the insurance payment scope within two years of market launch [2]. Dynamic Adjustment Mechanism - A dynamic adjustment mechanism for the insurance directory has been established, reducing the adjustment cycle from a maximum of 8 years to 1 year, allowing for a more responsive inclusion of new drugs [2]. - The proportion of new drugs approved within five years that are included in the insurance directory has increased from 32% in 2019 to an expected 98% in 2024 [2]. Negotiation and Renewal Rules - The NHSA has improved negotiation and renewal rules for innovative drugs, focusing on patient clinical benefits to determine pricing [3]. - The number of first-class innovative drugs approved has significantly increased, with 48 new approvals expected in 2024, marking a fivefold increase since 2018 [3]. Encouragement of True Innovation - The measures emphasize the importance of supporting genuine and differentiated innovation in the pharmaceutical industry, addressing challenges such as homogenization and unclear clinical value [4][5]. - Since 2018, 149 innovative drugs have been included in the insurance directory, with total fund expenditures reaching 4.1 trillion yuan, driving significant sales growth [4]. Global Market Development - The NHSA aims to facilitate the global market expansion of innovative drugs, with over 90 overseas licensing transactions completed by Chinese pharmaceutical companies in 2024, totaling over $50 billion [7]. - The measures include building platforms for overseas market access and encouraging commercial health insurance to invest in innovative drugs [7][8]. Clinical Application and Usage - The NHSA encourages timely access to innovative drugs in designated medical institutions and supports the establishment of green channels for procurement [9]. - Measures have been introduced to enhance the capacity of medical institutions to use innovative drugs effectively, including optimizing payment standards and supporting special case applications [10].